Quality is beyond debate, valuations are not
17/11/26 -"In the last couple of years, most of Roche’s peers – including Novartis, AstraZeneca, Novo Nordisk and Sanofi – have suffered important R&D setbacks, whereas the Swiss giant has avoided major ..."
Pages
69
Language
English
Published on
17/11/26
You may also be interested by these reports :
18/11/26
Leaving aside the mid-term profitability outlook downgrade in 2024, Lundbeck has often exceeded expectations with its operational delivery in the ...
17/11/26
In the last couple of years, most of Roche’s peers – including Novartis, AstraZeneca, Novo Nordisk and Sanofi – have suffered important R&D setbacks, ...
17/11/26
The factors discussed in the justification for DCF valuation have also prompted an upgrade to our NAV valuation. As a result, the target price resets ...
12/11/26
The Q3 results exceeded consensus estimates, backed by the strong showing of Electronics (driven by demand from AI applications) and healthy support ...